The futuristic exterior of Jumpcan Pharmaceutical's premises in Taixing. city. [Photo/WeChat account: txfabu]
A tomoxetine hydrochloride oral product manufactured by Jumpcan Pharmaceutical – based in Taixing city, Taizhou, in East China's Jiangsu province – recently got market approval for the treatment of attention deficit hyperactivity disorder, or ADHD in children and adolescents aged 6 years and above.
ADHD is one of the common mental disorders in childhood. Tomoxetine hydrochloride products were first developed by American company Eli Lilly, with its capsule dosage form product approved for market in November 2002.
Jumpcan Pharmaceutical's product is classified as Class 4 drug. According to the technical requirements that generic drugs should be consistent with the quality and efficacy of reference preparations, it was reviewed and approved.
In recent years, Jumpcan Pharmaceutical has continued to increase the research, development and introduction of new products. Since the start of this year, it has successively obtained production approvals for three types of medicine, meeting the different needs of patients.